We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics

By LabMedica International staff writers
Posted on 07 Aug 2019
Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
BioMérieux (Marcy-l'Étoile, France) showcased its unique and comprehensive range of diagnostic solutions that support the responsible use of antibiotics to improve patient care at AACC 2019. Among its diagnostic solutions highlighted at the tradeshow was Bact/Alert Virtuo, which along with bioMérieux’s Bact/Alert Virtuo blood culture system and Bact/Alert Fan Plus media, provides fast and actionable results for better antimicrobial stewardship.

BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.

At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.

BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Clinical Informatics Platform
CLARION™

Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
PURITAN MEDICAL